Review anchor
Glutathione reductase, mitochondrial
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Glutathione reductase, mitochondrial
CHEMBL2755
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Glutathione reductase, mitochondrial as ChEMBL target CHEMBL2755, mapped to UniProt P00390. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2755
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00390
Glutathione reductase, mitochondrial
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Glutathione reductase, mitochondrial matters
Glutathione reductase, mitochondrial is reviewed as Glutathione reductase, mitochondrial (UniProt P00390); Glutathione reductase, mitochondrial shows approved-linked disease relevance led by anaplastic astrocytoma. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 5 approved drugs, 301 compounds, and 104 assays, with lead potency reaching pChEMBL 8.4.
Protein context
Glutathione reductase, mitochondrial
Glutathione reductase, mitochondrial Sequence length is 522 aa.
Review this target as Glutathione reductase, mitochondrial, mapped to UniProt P00390. Sequence length is 522 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P00390
Protein
Disease context
anaplastic astrocytoma
Glutathione reductase, mitochondrial shows approved-linked disease relevance led by anaplastic astrocytoma. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CARMUSTINE.
Start review with anaplastic astrocytoma because it currently carries approved-linked support. Linked drugs include CARMUSTINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 5 approved drugs, 301 compounds, and 104 assays for this target. The dominant activity type is IC50. CHEMBL120147 is the current potency anchor at pChEMBL 8.4.
Use CHEMBL120147 as the tractability anchor when discussing potency (pChEMBL 8.4).
Activity source · ChEMBL 36 via Core Engine
5 approved
pChEMBL 8.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Glutathione reductase, mitochondrial matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00390, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why anaplastic astrocytoma is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
301
Total Compounds
104
Total Assays
5
Approved Drugs
IC50: 240.0, KI: 27.0, KD: 2.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL120147
|
8.4 | IC50 | — |
|
|
No preferred name
CHEMBL1824793
|
6.7 | Ki | — |
|
|
No preferred name
CHEMBL1824793
|
6.5 | IC50 | — |
|
|
No preferred name
CHEMBL5425052
|
6.2 | IC50 | — |
|
|
No preferred name
CHEMBL135536
|
6.1 | IC50 | — |
Source Header